Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (3): 233-239.doi: 10.3969/j.issn.1000-6621.2021.03.008
• Original Articles • Previous Articles Next Articles
YAO Xu, WU Cheng-guo, GONG De-hua, YAO Yu-xia, ZHANG Can-you, XU Cai-hong, XIA Yin-yin, CHEN Hui, CHENG Jun(), ZHANG Hui()
Received:
2020-12-22
Online:
2021-03-10
Published:
2021-03-03
Contact:
CHENG Jun,ZHANG Hui
E-mail:chengjun@chinacdc.cn;zhanghui@chinacdc.cn
YAO Xu, WU Cheng-guo, GONG De-hua, YAO Yu-xia, ZHANG Can-you, XU Cai-hong, XIA Yin-yin, CHEN Hui, CHENG Jun, ZHANG Hui. Analysis of treatment completeness and its influencing factors of 12-week preventive therapy among close contacts of pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 233-239. doi: 10.3969/j.issn.1000-6621.2021.03.008
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.03.008
基本特征 | 服药例数 | 构成比(%) | 基本特征 | 服药例数 | 构成比(%) |
---|---|---|---|---|---|
年龄(岁)a | 是否饮酒 | ||||
5~17 | 230 | 23.54 | 是 | 218 | 22.04 |
18~34 | 154 | 15.76 | 否 | 771 | 77.96 |
35~49 | 275 | 28.15 | 有无卡介苗接种卡痕 | ||
50~64 | 318 | 32.55 | 有 | 702 | 70.98 |
性别 | 无 | 287 | 29.02 | ||
男 | 400 | 40.44 | 是否与病原学阳性肺结核患者共同居住d | ||
女 | 589 | 59.56 | 是 | 648 | 65.59 |
职业b | 否 | 340 | 34.41 | ||
学生 | 269 | 27.23 | 负责预防性服药的机构 | ||
家务及待业 | 257 | 26.01 | 疾病预防控制中心 | 216 | 21.84 |
农、牧、渔(船)民 | 203 | 20.55 | 结核病防治所 | 182 | 18.40 |
其他 | 259 | 26.21 | 定点医院 | 591 | 59.76 |
文化程度c | 服药管理方式 | ||||
初中及以下 | 758 | 76.72 | 自我管理 | 464 | 46.92 |
高中及以上 | 230 | 23.28 | 家庭成员督导 | 201 | 20.32 |
是否吸烟 | 村医督导 | 324 | 32.76 | ||
是 | 135 | 13.65 | |||
否 | 854 | 86.35 |
影响因素 | 服药例数 | 完成服药例数 | 完成率(%) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
性别 | 0.495 | 0.482 | ||||||
男 | 400 | 363 | 90.75 | |||||
女 | 589 | 542 | 92.02 | |||||
年龄(岁)a | 14.906 | 0.002 | ||||||
5~17 | 230 | 221 | 96.09 | |||||
18~34 | 154 | 142 | 92.21 | |||||
35~49 | 275 | 255 | 92.73 | |||||
50~64 | 318 | 277 | 87.11 | |||||
职业b | 11.543 | 0.001 | ||||||
学生 | 269 | 256 | 95.17 | |||||
家务及待业 | 257 | 233 | 90.66 | |||||
农、牧、渔(船)民 | 203 | 189 | 93.10 | |||||
其他 | 259 | 226 | 87.26 | |||||
影响因素 | 服药例数 | 完成服药例数 | 完成率(%) | χ2值 | P值 | |||
文化程度c | 0.152 | 0.697 | ||||||
初中及以下 | 758 | 695 | 91.69 | |||||
高中及以上 | 230 | 209 | 90.87 | |||||
是否吸烟 | 8.038 | 0.005 | ||||||
是 | 135 | 115 | 85.19 | |||||
否 | 854 | 790 | 92.51 | |||||
是否饮酒 | 4.241 | 0.039 | ||||||
是 | 218 | 192 | 88.07 | |||||
否 | 771 | 713 | 92.48 | |||||
有无卡介苗接种卡痕 | 0.719 | 0.396 | ||||||
有 | 702 | 639 | 91.03 | |||||
无 | 287 | 266 | 92.68 | |||||
是否与病原学阳性肺结核患者共同居住d | 0.879 | 0.348 | ||||||
是 | 648 | 589 | 90.90 | |||||
否 | 340 | 315 | 92.65 | |||||
负责预防性服药的机构 | 9.559 | 0.008 | ||||||
疾病预防控制中心 | 216 | 208 | 96.30 | |||||
结核病防治所 | 182 | 168 | 92.31 | |||||
定点医院 | 591 | 529 | 89.51 | |||||
服药管理方式 | 0.804 | 0.669 | ||||||
自我管理 | 464 | 428 | 92.24 | |||||
家庭成员督导 | 201 | 184 | 91.54 | |||||
村医督导 | 324 | 293 | 90.43 |
变量 | β值 | s | Wald χ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
年龄(岁) | |||||
5~17 | - | - | - | - | 1.00 |
18~34 | 0.66 | 0.46 | 2.02 | 0.155 | 1.93(0.78~4.78) |
35~49 | 0.65 | 0.42 | 2.37 | 0.124 | 1.91(0.84~4.37) |
50~64 | 1.31 | 0.39 | 11.10 | <0.01 | 3.71(1.72~8.02) |
是否吸烟 | |||||
是 | 0.58 | 0.29 | 4.07 | 0.044 | 1.79(1.02~3.13) |
否 | - | - | - | - | 1.00 |
负责预防性服药的机构 | |||||
疾病预防控制中心 | - | - | - | - | 1.00 |
结核病防治所 | 0.98 | 0.50 | 3.84 | 0.051 | 2.67(0.99~7.15) |
定点医院 | 1.51 | 0.44 | 11.77 | <0.01 | 4.51(1.91~10.65) |
[1] |
Reichler MR, Khan A, Sterling TR, et al. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. J Infect Dis, 2018,218(6):1000-1008. doi: 10.1093/infdis/jiy265.
doi: 10.1093/infdis/jiy265 URL pmid: 29767733 |
[2] |
Park SY, Han S, Kim YM, et al. Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea. Sci Rep, 2020,10(1):1306. doi: 10.1038/s41598-020-57697-1.
URL pmid: 31992740 |
[3] |
Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014,161(6):419-428. doi: 10.7326/M14-1019.
doi: 10.7326/M14-1019 URL pmid: 25111745 |
[4] |
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020,69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
doi: 10.15585/mmwr.rr6901a1 URL pmid: 32053584 |
[5] | U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. 2010-06-14. |
[6] | 孙振球. 医学统计学.3版. 北京: 人民卫生出版社, 2010. |
[7] |
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166. doi: 10.1056/NEJMoa1104875.
URL pmid: 22150035 |
[8] | Huang YW, Yang SF, Yeh YP, et al. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (Baltimore), 2016,95(34):e4126. doi: 10.1097/MD.0000000000004126. |
[9] |
Schmit KM, Lobato MN, Lang SG, et al. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons. J Public Health Manag Pract, 2019,25(2):E1-E6. doi: 10.1097/PHH.0000000000000822.
doi: 10.1097/PHH.0000000000000822 URL pmid: 30024493 |
[10] | Villa S, Ferrarese M, Sotgiu G, et al. Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. J Clin Med, 2019,9(1):101. doi: 10.3390/jcm9010101. |
[11] |
Onwubiko U, Wall K, Sales RM, et al. Using Directly Observed Therapy (DOT) for latent tuberculosis treatment-A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA. PLoS One, 2019,14(6):e0218373. doi: 10.1371/journal.pone.0218373.
URL pmid: 31226132 |
[12] |
Lam CK, McGinnis Pilote K, Haque A, et al. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res, 2018,20(11):e287. doi: 10.2196/jmir.9825.
doi: 10.2196/jmir.9825 URL pmid: 30459146 |
[13] |
Hirsch-Moverman Y, Colson PW, Bethel J, et al. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis, 2013,17(9):1178-1185. doi: 10.5588/ijtld.12.0823.
URL pmid: 23928167 |
[14] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[15] |
Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis, 2015,61(4):527-535. doi: 10.1093/cid/civ323.
doi: 10.1093/cid/civ323 URL pmid: 25904367 |
[16] |
Jo KW, Kim JS, Kwon HS, et al. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. Respir Med, 2019,158:42-48. doi: 10.1016/j.rmed.2019.10.005.
URL pmid: 31605920 |
[17] |
Sentís A, Vasconcelos P, Machado RS, et al. Failure to complete treatment for latent tuberculosis infection in Portugal, 2013—2017: geographic-, sociodemographic-, and medical-associated factors. Eur J Clin Microbiol Infect Dis, 2020,39(4):647-656. doi: 10.1007/s10096-019-03765-y.
doi: 10.1007/s10096-019-03765-y URL pmid: 31797155 |
[18] |
Plourde PJ, Basham CA, Derksen S, et al. Latent tuberculosis treatment completion rates from prescription drug administrative data. Can J Public Health, 2019,110(6):705-713. doi: 10.17269/s41997-019-00240-1.
doi: 10.17269/s41997-019-00240-1 URL pmid: 31297736 |
[19] |
Bennett RJ, Brodine S, Waalen J, et al. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health, 2014,104(4):e95-e102. doi: 10.2105/AJPH.2013.301637.
URL pmid: 24524534 |
[20] |
Eastment MC, McClintock AH, McKinney CM, et al. Factors That Influence Treatment Completion for Latent Tuberculosis Infection. J Am Board Fam Med, 2017,30(4):520-527. doi: 10.3122/jabfm.2017.04.170070.
doi: 10.3122/jabfm.2017.04.170070 URL pmid: 28720633 |
[21] | 谷战英, 孙强, 姚静静. 定点医院模式实施前后结核病控制效果分析. 中国公共卫生, 2017,33(1):84-87. doi: 10.11847/zgggws2017-33-01-21. |
[1] | MA Yan, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317. |
[2] | DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321. |
[3] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[4] | GE Qi-ping, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334. |
[5] | ZHANG Li-jie, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340. |
[6] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui, LI Cheng-cheng. Analysis of CT features of drug-resistant pulmonary tuberculosis with cavity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 341-345. |
[7] | YU Shan, LI Zhi-ming, XU Chun-xia, WANG Tao. Analysis of risk factors associated with false negative results of interferon-gamma release assays on peripheral blood from tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 346-351. |
[8] | LIU Ting, WANG Liang, YANG Mei. The study on the anti-tuberculosis activity of polymorphonuclear cell from peripheral blood of patients with multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 352-356. |
[9] | ZHANG Chen-chen, TAN Wei-guo, GUO Hui-xin, HUANG Xin-chun, CHEN Yan-mei, WEI Wen-jing. The effect of Mycobacterium tuberculosis infection on sputum flora structure [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 357-363. |
[10] | BAI Hua, GUO Jing-wei, HU Pei-lei, YI Song-lin, WEN Jia, LIU Feng-ping, TAN Yun-hong, BAI Li-qiong. Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Hu’nan Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 364-369. |
[11] | WANG Huan, SHEN Xin, CHEN Jing, XIA Zhen, XU Biao, YUAN Zheng-an. Analysis of the epidemiological characteristics of pulmonary tuberculosis among migrants in Shanghai from 2008 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 370-377. |
[12] | MA Zhi-tao, WANG Na, LYU Yang, HU Wei-hong, CHEN Chang, HE Fan, SHEN Xin, LIU Xiao-feng. The research on psychological status of pulmonary tuberculosis patients and influencing factors in Baoshan District, Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 378-384. |
[13] | LI Zhi-hong, GU Kan-kai, YAO Jing, ZHANG Huai-qing, HAN Zhi-ying, SHEN Xin, CHEN Jing, SHEN Bing. Analysis of screening of close contacts of a tuberculosis patient in a kindergarten in downtown Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 385-390. |
[14] | LIU Zhen-jiang, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[15] | ZHOU Shuang, CHEN Nan, ZHU Kun, JIANG Hui, YANG Lei, DU Jian. Investigation of the experience of tuberculosis patients for follow up using the internet platform [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 398-403. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||